Cargando…

Advancement of secretory breast carcinoma: a narrative review

BACKGROUND AND OBJECTIVE: Secretory breast carcinoma (SBC) is a rare breast malignancy. Most available studies on SBC are case reports or small case series, and the few large-sample studies available lack critical information due to database limitations. To improve the understanding of SBC and provi...

Descripción completa

Detalles Bibliográficos
Autores principales: Min, Ningning, Zhu, Jingjin, Liu, Mei, Li, Xiru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708487/
https://www.ncbi.nlm.nih.gov/pubmed/36467350
http://dx.doi.org/10.21037/atm-22-2491
_version_ 1784840945083088896
author Min, Ningning
Zhu, Jingjin
Liu, Mei
Li, Xiru
author_facet Min, Ningning
Zhu, Jingjin
Liu, Mei
Li, Xiru
author_sort Min, Ningning
collection PubMed
description BACKGROUND AND OBJECTIVE: Secretory breast carcinoma (SBC) is a rare breast malignancy. Most available studies on SBC are case reports or small case series, and the few large-sample studies available lack critical information due to database limitations. To improve the understanding of SBC and provide a reference for clinical practice, we systematically reviewed the demographic, clinical, pathologic, and genetic characteristics of SBC, as well as its treatment and prognosis. METHODS: We conducted a PubMed search with the keywords “secretory breast carcinoma” or “juvenile breast carcinoma”. Relevant English-language publications published from January 1966 to February 2022 were screened manually at 3 levels—title, abstract, and full text—to identify the articles that presented the demographic, clinical, pathologic, and genetic characteristics of SBC, as well as its treatment and prognosis. KEY CONTENT AND FINDINGS: SBC lacks specific clinical manifestations and has typical pathological and molecular characteristics, including intracellular and extracellular eosinophilic secretions, immune spectrum similar to hormone receptor-positive tumors, and the ETV6-NTRK3 fusion gene. Surgery remains the primary treatment for SBC. Postoperative radiotherapy is recommended by most researchers for adult SBC but not for pediatric patients. The evidence of chemotherapy and endocrine therapy is insufficient, and targeted therapy of the ETV6-NTRK3 fusion gene shows a good response. Most patients with SBC have a good prognosis except for a few patients who experience distant metastases. Future studies will be focused on the molecular characteristics of those patients with SBC who have a poor prognosis. CONCLUSIONS: The development of histopathology and molecular genetics has promoted the progress of the clinical diagnosis of SBC. The purpose of this review is to serve as a guide for the better clinical treatment of SBC, particularly in the areas of disease identification and prognosis classification for patients.
format Online
Article
Text
id pubmed-9708487
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-97084872022-12-01 Advancement of secretory breast carcinoma: a narrative review Min, Ningning Zhu, Jingjin Liu, Mei Li, Xiru Ann Transl Med Review Article BACKGROUND AND OBJECTIVE: Secretory breast carcinoma (SBC) is a rare breast malignancy. Most available studies on SBC are case reports or small case series, and the few large-sample studies available lack critical information due to database limitations. To improve the understanding of SBC and provide a reference for clinical practice, we systematically reviewed the demographic, clinical, pathologic, and genetic characteristics of SBC, as well as its treatment and prognosis. METHODS: We conducted a PubMed search with the keywords “secretory breast carcinoma” or “juvenile breast carcinoma”. Relevant English-language publications published from January 1966 to February 2022 were screened manually at 3 levels—title, abstract, and full text—to identify the articles that presented the demographic, clinical, pathologic, and genetic characteristics of SBC, as well as its treatment and prognosis. KEY CONTENT AND FINDINGS: SBC lacks specific clinical manifestations and has typical pathological and molecular characteristics, including intracellular and extracellular eosinophilic secretions, immune spectrum similar to hormone receptor-positive tumors, and the ETV6-NTRK3 fusion gene. Surgery remains the primary treatment for SBC. Postoperative radiotherapy is recommended by most researchers for adult SBC but not for pediatric patients. The evidence of chemotherapy and endocrine therapy is insufficient, and targeted therapy of the ETV6-NTRK3 fusion gene shows a good response. Most patients with SBC have a good prognosis except for a few patients who experience distant metastases. Future studies will be focused on the molecular characteristics of those patients with SBC who have a poor prognosis. CONCLUSIONS: The development of histopathology and molecular genetics has promoted the progress of the clinical diagnosis of SBC. The purpose of this review is to serve as a guide for the better clinical treatment of SBC, particularly in the areas of disease identification and prognosis classification for patients. AME Publishing Company 2022-11 /pmc/articles/PMC9708487/ /pubmed/36467350 http://dx.doi.org/10.21037/atm-22-2491 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Review Article
Min, Ningning
Zhu, Jingjin
Liu, Mei
Li, Xiru
Advancement of secretory breast carcinoma: a narrative review
title Advancement of secretory breast carcinoma: a narrative review
title_full Advancement of secretory breast carcinoma: a narrative review
title_fullStr Advancement of secretory breast carcinoma: a narrative review
title_full_unstemmed Advancement of secretory breast carcinoma: a narrative review
title_short Advancement of secretory breast carcinoma: a narrative review
title_sort advancement of secretory breast carcinoma: a narrative review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708487/
https://www.ncbi.nlm.nih.gov/pubmed/36467350
http://dx.doi.org/10.21037/atm-22-2491
work_keys_str_mv AT minningning advancementofsecretorybreastcarcinomaanarrativereview
AT zhujingjin advancementofsecretorybreastcarcinomaanarrativereview
AT liumei advancementofsecretorybreastcarcinomaanarrativereview
AT lixiru advancementofsecretorybreastcarcinomaanarrativereview